Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma

This study aimed to examine whether inhibition of hexokinase (HK)-II activity enhances the efficacy of sorafenib in in-vivo models of hepatocellular carcinoma (HCC), and to evaluate the prognostic implication of HK-II expression in patients with HCC. We used 3-bromopyruvate (3-BP), a HK-II inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Jeong-Ju, Yu, Su Jong, Na, Juri, Kim, Kyungmin, Cho, Young Youn, Lee, Yun Bin, Cho, Eun Ju, Lee, Jeong-Hoon, Kim, Yoon Jun, Youn, Hyewon, Yoon, Jung-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471302/
https://www.ncbi.nlm.nih.gov/pubmed/30875800
http://dx.doi.org/10.3390/ijms20061292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471302/
https://www.ncbi.nlm.nih.gov/pubmed/30875800
http://dx.doi.org/10.3390/ijms20061292

Ejemplares similares